These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 33547681)
1. Achieving a low human dose for targeted covalent drugs: Pharmacokinetic and pharmacodynamic considerations on target characteristics and drug attributes. Yang Z Biopharm Drug Dispos; 2021 Apr; 42(4):150-159. PubMed ID: 33547681 [TBL] [Abstract][Full Text] [Related]
2. Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS-986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo-controlled trial in healthy participants. Catlett IM; Nowak M; Kundu S; Zheng N; Liu A; He B; Girgis IG; Grasela DM Br J Clin Pharmacol; 2020 Sep; 86(9):1849-1859. PubMed ID: 32198939 [TBL] [Abstract][Full Text] [Related]
3. Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK). Watterson SH; Liu Q; Beaudoin Bertrand M; Batt DG; Li L; Pattoli MA; Skala S; Cheng L; Obermeier MT; Moore R; Yang Z; Vickery R; Elzinga PA; Discenza L; D'Arienzo C; Gillooly KM; Taylor TL; Pulicicchio C; Zhang Y; Heimrich E; McIntyre KW; Ruan Q; Westhouse RA; Catlett IM; Zheng N; Chaudhry C; Dai J; Galella MA; Tebben AJ; Pokross M; Li J; Zhao R; Smith D; Rampulla R; Allentoff A; Wallace MA; Mathur A; Salter-Cid L; Macor JE; Carter PH; Fura A; Burke JR; Tino JA J Med Chem; 2019 Apr; 62(7):3228-3250. PubMed ID: 30893553 [TBL] [Abstract][Full Text] [Related]
4. Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose. Xiong W; Friese-Hamim M; Johne A; Stroh C; Klevesath M; Falchook GS; Hong DS; Girard P; El Bawab S CPT Pharmacometrics Syst Pharmacol; 2021 May; 10(5):428-440. PubMed ID: 33818908 [TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib. Tam CS; Ou YC; Trotman J; Opat S Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1329-1344. PubMed ID: 34491123 [No Abstract] [Full Text] [Related]
6. Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases. Caldwell RD; Qiu H; Askew BC; Bender AT; Brugger N; Camps M; Dhanabal M; Dutt V; Eichhorn T; Gardberg AS; Goutopoulos A; Grenningloh R; Head J; Healey B; Hodous BL; Huck BR; Johnson TL; Jones C; Jones RC; Mochalkin I; Morandi F; Nguyen N; Meyring M; Potnick JR; Santos DC; Schmidt R; Sherer B; Shutes A; Urbahns K; Follis AV; Wegener AA; Zimmerli SC; Liu-Bujalski L J Med Chem; 2019 Sep; 62(17):7643-7655. PubMed ID: 31368705 [TBL] [Abstract][Full Text] [Related]
7. Label-Free Bottom-Up Proteomic Workflow for Simultaneously Assessing the Target Specificity of Covalent Drug Candidates and Their Off-Target Reactivity to Selected Proteins. Yang Y; Shu YZ; Humphreys WG Chem Res Toxicol; 2016 Jan; 29(1):109-16. PubMed ID: 26675335 [TBL] [Abstract][Full Text] [Related]
8. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor. Wong H; Vernillet L; Peterson A; Ware JA; Lee L; Martini JF; Yu P; Li C; Del Rosario G; Choo EF; Hoeflich KP; Shi Y; Aftab BT; Aoyama R; Lam ST; Belvin M; Prescott J Clin Cancer Res; 2012 Jun; 18(11):3090-9. PubMed ID: 22496205 [TBL] [Abstract][Full Text] [Related]
9. Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase. Palani S; Patel M; Huck J; Zhang M; Balani SK; Yang J; Chen S; Mettetal J; Manfredi M; Shyu WC; Ecsedy JA; Chakravarty A Cancer Chemother Pharmacol; 2013 Dec; 72(6):1255-64. PubMed ID: 24101146 [TBL] [Abstract][Full Text] [Related]
10. Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor. Herman AE; Chinn LW; Kotwal SG; Murray ER; Zhao R; Florero M; Lin A; Moein A; Wang R; Bremer M; Kokubu S; Serone AP; Hanze EL; Viberg A; Morimoto AM; Winter HR; Katsumoto TR Clin Pharmacol Ther; 2018 Jun; 103(6):1020-1028. PubMed ID: 29484638 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics/pharmacodynamics model-supported early drug development. Chen B; Dong JQ; Pan WJ; Ruiz A Curr Pharm Biotechnol; 2012 Jun; 13(7):1360-75. PubMed ID: 22201585 [TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. Marostica E; Sukbuntherng J; Loury D; de Jong J; de Trixhe XW; Vermeulen A; De Nicolao G; O'Brien S; Byrd JC; Advani R; McGreivy J; Poggesi I Cancer Chemother Pharmacol; 2015 Jan; 75(1):111-21. PubMed ID: 25381051 [TBL] [Abstract][Full Text] [Related]
13. Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics. Agoram BM Br J Clin Pharmacol; 2009 Feb; 67(2):153-60. PubMed ID: 19076987 [TBL] [Abstract][Full Text] [Related]
14. The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor. Maynard J; Emmas SA; Ble FX; Barjat H; Lawrie E; Hancox U; Polanska UM; Pritchard A; Hudson K PLoS One; 2017; 12(8):e0183048. PubMed ID: 28806782 [TBL] [Abstract][Full Text] [Related]
15. Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling. Ploeger BA; van der Graaf PH; Danhof M Drug Metab Pharmacokinet; 2009; 24(1):3-15. PubMed ID: 19252332 [TBL] [Abstract][Full Text] [Related]
16. Human microdosing and mice xenograft data of AGM-130 applied to estimate efficacious doses in patients. Park WS; Park GJ; Han S; Ban S; Park MY; Kim SH; Kim SM; Kim YC; Kim HS; Shin YG; Yim DS Cancer Chemother Pharmacol; 2017 Aug; 80(2):363-369. PubMed ID: 28660432 [TBL] [Abstract][Full Text] [Related]
17. Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies. Bauer RA Drug Discov Today; 2015 Sep; 20(9):1061-73. PubMed ID: 26002380 [TBL] [Abstract][Full Text] [Related]
18. Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase. Guo Y; Liu Y; Hu N; Yu D; Zhou C; Shi G; Zhang B; Wei M; Liu J; Luo L; Tang Z; Song H; Guo Y; Liu X; Su D; Zhang S; Song X; Zhou X; Hong Y; Chen S; Cheng Z; Young S; Wei Q; Wang H; Wang Q; Lv L; Wang F; Xu H; Sun H; Xing H; Li N; Zhang W; Wang Z; Liu G; Sun Z; Zhou D; Li W; Liu L; Wang L; Wang Z J Med Chem; 2019 Sep; 62(17):7923-7940. PubMed ID: 31381333 [TBL] [Abstract][Full Text] [Related]
19. Population PK-PD Modeling of Circulating Lymphocyte Dynamics in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment. Gallais F; Ysebaert L; Despas F; De Barros S; Obéric L; Allal B; Chatelut E; White-Koning M Clin Pharmacol Ther; 2021 Jul; 110(1):220-228. PubMed ID: 33539551 [TBL] [Abstract][Full Text] [Related]
20. HZ-A-005, a potent, selective, and covalent Bruton's tyrosine kinase inhibitor in preclinical development. Huang W; Wang S; Zhang Z; Zhang C; Zeng S; Liang M; Shen Z; Liu X Bioorg Chem; 2020 Dec; 105():104377. PubMed ID: 33091668 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]